Table 2 Socio-demographic and clinical characteristics of patients who participated in the validation study (N = 588)
Variable | Investigational group | Two control groups | |||
|---|---|---|---|---|---|
ACR + (N = 137) | ACR' (N = 139) | FM (N = 158) | Non-FM (N = 154) | ||
Country - N (%) | Germany | 45 (32.8) | 62 (44.6) | 41 (25.9) | 36 (23.4) |
France | 92 (67.2) | 77 (55.4) | 117 (74.1) | 118 (76.6) | |
Age (years) | N | 137 | 139 | 158 | 154 |
Mean (SD) | 51.5 (11.0) | 52.3 (14.0) | 52.0 (11.6) | 55.3 (14.6) | |
Median (Q1 - Q3) | 52.0 (46.0 - 58.0) | 52.0 (43.0 - 61.0) | 53.0 (44.0 - 59.0) | 55.0 (46.0 - 65.0) | |
Min - Max | 19.0 - 87.0 | 19.0 - 89.0 | 25.0 - 87.0) | 18.0 - 83.0) | |
Gender - N (%) | Female | 118 (86.1) | 114 (82.0) | 145 (91.8) | 109 (70.8) |
Time since first chronic widespread pain (years) | N | 129 | 137 | 152 | - |
Mean (SD) | 6.1 (6.8) | 5.5 (7.7) | 9.9 (9.6) | ||
Median (Q1 - Q3) | 4.0 (1.0 - 9.0) | 3.0 (1.0 - 5.0) | 7.0 (4.0 - 13.0) | ||
Min - Max | 0.0 - 36.0 | 0.0 - 42.0 | 0.0 - 62.0 | ||
Number of doctors already visited for pain and/or fatigue - N (%) | First doctor | 7 (5.1) | 6 (4.3) | 4 (2.5) | - |
2-5 | 106 (77.4) | 113 (81.3) | 95 (60.1) | ||
> 5 | 21 (15.3) | 20 (14.4) | 52 (32.9) | ||
Number of tender points - N (%) | < 11 | 18 (13.1) | 124 (89.2) | - | - |
≥ 11 | 119 (86.9) | 15 (10.8) | |||